Clinical Trials Browser

Phase 3 × Active not recruiting × Urinary Bladder Neoplasms × Clear all

NCT05092958 2026-04-21

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04658862 2026-04-13

SunRISe-2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT05714202 2026-04-13

SunRISe-3

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 2 FDA

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04165317 2026-01-22

CREST

Phase 3 Active not recruiting

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Phase 3 Active not recruiting

595 enrolled 2 FDA

Urinary Bladder Neoplasms

NCT05704244 2025-08-28

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03757949 2025-05-15

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Phase 3 Active not recruiting

203 enrolled 9 charts

Urinary Bladder Neoplasms

NCT05776758 2025-04-16

Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT02951325 2025-02-13

BART

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03799835 2024-12-11

ALBAN

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 2 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05822934 2024-07-30

Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms